Effects of the androgen receptor inhibitor enzalutamide on the pharmacokinetics of dolutegravir and tenofovir: a case report

Enzalutamide is an androgen receptor inhibitor used for the treatment of prostate cancer. Although enzalutamide causes a favorable adverse effect profile, it might cause drug-drug interactions with some antiretrovirals. No major differences on the main dolutegravir and tenofovir pharmokinetocs were observed in this case report when comparing baseline assessments with those following the introduction of enzalutamide, also when given at higher doses, in a 63-year-old male living with HIV and prostate cancer.

Automated summary

Enzalutamide, an androgen receptor inhibitor used for prostate cancer treatment, may interact with some antiretrovirals. However, this case report found no significant pharmacokinetic differences in the main antiretrovirals, dolutegravir and tenofovir, after the introduction of enzalutamide, even at higher doses.